Related Experiment Video
Updated: Jul 7, 2026

Ear Plaster Therapy as a Safe and Effective Treatment for Gestational Vomiting
Published on: August 4, 2023
Supraphysiological doses of intravenous PYY3-36 cause nausea, but no additional reduction in food intake
Carel W le Roux1, Cynthia M Borg, Kevin G Murphy
1Department of Metabolic Medicine, 6th Floor Commonwealth Building, Hammersmith Hospital, Imperial College London, London, UK.
Background:
Peptide YY (PYY(3-36)) infused to levels within the physiological range reduces appetite and food intake in humans without nausea. However, PYY(3-36) has previously been shown to cause nausea at higher doses.
Methods:
We studied the relationship of PYY(3-36), nausea and food intake in six volunteers, using three different PYY(3-36) preparations infused to achieve supraphysiological PYY plasma levels.
Results:
Supraphysiological levels of PYY caused nausea in five subjects (P < 0.05). Although PYY(3-36) increased satiety (P < 0.05) and reduced food intake (P < 0.05), no greater enhancement of satiety or inhibition of food intake was observed compared with previous reports.
Conclusions:
This study cautions against the use of supraphysiological doses of PYY(3-36) as it may increase nausea with no benefit in food reduction.
Related Concept Videos
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
Phenothiazines, such as prochlorperazine...
Prevention of Further Absorption of Poison
Drug Toxicity: Dose-Dependent Reactions
Parenteral Anesthetics: Overview
